Promising cancer drug blocked by regulatory limbo

A father reports that his 15-year-old son with metastatic osteosarcoma cannot access RisRez: approved in China but not marketed, while GSK's international trial has filled all spots. This case illustrates the regulatory limbo separating patients from treatments that have successfully completed Phase 3.

There is a medication called RisRez. It is an antibody that marks tumor cells for destruction by the body itself and also blocks one of the mechanisms cancer cells use to hide from the immune system. In China, it passed Phase 3, the final stage before approval, with results described as spectacular. The trial has ended, and the dossier awaits Chinese government authorization for official use to replace current classic chemotherapy-based treatments.

## Regulatory limbo leaves patient without drug

While that approval arrives, RisRez is in no man's land. In China, it cannot be accessed via clinical trials because they are closed, nor purchased because it is not authorized for sale. This is the common paradox of drugs finishing research before paperwork: the medicine exists, has proven what it needed to prove, yet is unavailable to anyone.

In the rest of the world, RisRez rights belong to **GSK**. The pharmaceutical company launched a trial to validate results obtained in China. That trial peine few spots in June and filled them immediately. For a Spanish patient with metastatic osteosarcoma, the door is not open.

## What is osteosarcoma and why this case is delicate

Osteosarcoma is a rare bone tumor appearing mostly in children and adolescents. When it metastasizes to lungs, as in this case, prognosis worsens and therapeutic options narrow. The patient discussed here is **15 years old**, on palliative care since July, and has undergone two bilateral thoracotomies, leaving scars on his back after surgeries to remove lung nodules.

The treating oncologist, according to the account, does what she can: overwhelmed, seeking permissions, moving things, but weeks pass. The **EMBOLD Sarcoma 202** trial no longer accepts candidates and has a waiting list. That was the final blow for the family.

## Costs and affordability

The family estimates treatment in China at around **€70,000**, the price of a good new car. That money is not the obstacle: the father claims he would sell his house if needed and asks no one for funds. The problem is elsewhere. Requesting compassionate use from GSK risks being blocked. Paying out-of-pocket, he argues, would be worse: accepting system failure instead of forcing a solution.

One fact must not be overlooked: in Spain, lung cancer treatments approved in Italy are not authorized here, reportedly to avoid paying for them. This is not a Spanish rarity. Health technology assessment and price negotiations with pharma companies are slow processes in nearly all public systems, and differences between approvals across countries can span years.

## A question with no easy answer

What can a family do in this situation? Compassionate use pathways exist, allowing requests for unauthorized drugs for specific patients, but depend on companies and administrations. Clinical trial pathways are closed. Out-of-pocket payment clashes with systemic logic. Meanwhile, the son weakens.

This article offers no medical or legal answers to that father. It only describes the mechanism trapping him: a drug that passed Phase 3 in China, controlled by **GSK** globally, currently unavailable there or here. Any oncological treatment decision must always be consulted with the patient’s medical team.